In October 2025, AIVIS, an AI pathology company, attended and presented at Pathology Visions 2025, one of the world’s largest conferences in digital and computational pathology. The company showcased its latest AI-powered diagnostic solutions and research achievements while strengthening global collaborations. Organized by the Digital Pathology Association (DPA), Pathology Visions brings together global leaders in pathology and life sciences to explore cutting-edge technologies shaping the future of diagnostics. At the event, AIVIS highlighted its technological excellence and explored strategic partnerships across the digital pathology ecosystem. Unveiling the “QuaCCa-BRS Ki-67” Benchmark Dataset During the conference, AIVIS unveiled its large-scale benchmark dataset for breast cancer Ki-67 quantitative analysis, named “QuaCCa-BRS Ki-67” (QuaCCa), for the first time. The dataset encompasses a wide range of histological patterns and cell types, meticulously annotated at the cellular level. “We’ve established a critical foundation for objectively validating and standardizing the performance of AI models,” said an AIVIS spokesperson. “This effort enhances the reliability of AI diagnostic solutions, contributes to patient safety, and accelerates the clinical adoption of automated pathology systems.” Showcasing Qanti® IHC and AstraZeneca Collaboration AIVIS also showcased its flagship AI-powered biomarker quantification software, Qanti® IHC, which quantitatively analyzes the expression of key biomarkers—including ER, PR, HER2, and Ki-67—from IHC images to assist pathologists in diagnosis. The company highlighted its recent collaboration with AstraZeneca to build an “AI-based HER2 diagnostic ecosystem,” reinforcing AIVIS’s leadership in precision medicine. At the event, AIVIS presented Qanti® IHC’s high accuracy, validated through the QuaCCa dataset (Pearson correlation coefficient = 0.979), and discussed potential collaborations with global pharmaceutical companies and AI marketplace partners. Presenting Qanti® Micro for Accessible AI Pathology AIVIS also introduced Qanti® Micro, a groundbreaking solution designed to make AI-driven computational pathology more accessible. Unlike conventional digital pathology systems that rely on expensive whole-slide scanners, Qanti® Micro enables biomarker analysis directly from images captured with a standard optical microscope and camera. This innovation allows small- to mid-sized hospitals and research laboratories to perform AI-based quantitative analysis at an affordable cost, significantly improving diagnostic efficiency and workflow convenience. Setting a New Standard in AI-Driven Computational Pathology “Participating in Pathology Visions 2025 was a key milestone for AIVIS,” said Daehong Lee, CEO of AIVIS. “By introducing the ‘QuaCCa’ dataset and showcasing our collaboration with AstraZeneca, along with the competitiveness of the Qanti® product family, we demonstrated our potential to set new global standards in AI-driven computational pathology and accelerate international expansion.”